Research Article | | Peer-Reviewed

Centralized Faith-based Pharmaceutical Supply Chain Performance in Cameroon: A System-level Audit

Received: 16 June 2026     Accepted: 30 June 2026     Published: 22 July 2026
Views:       Downloads:
Abstract

Background: Centralized pharmaceutical procurement can strengthen medicine quality assurance and reduce exposure to substandard and falsified medicines in low- and middle-income countries. However, medicine availability depends on how well procurement, forecasting, warehousing, inventory management, information systems, and distribution function as an integrated system. This study assessed the system-level performance of a centralized, faith-based pharmaceutical supply chain in Cameroon to identify operational strengths, performance gaps, and governance-related risks that affect sustained access to quality-assured medicines. Methods: A cross-sectional pharmaceutical supply chain audit was conducted over a 1-year period using the Pharmaceutical Supply Chain Initiative tripartite audit framework. Performance was assessed across forecasting, procurement, supplier sourcing, warehousing, inventory management, use of logistics management information systems, and distribution, using adapted USAID-recommended indicators. Quantitative benchmarking was complemented by participatory root-cause analysis using the Ishikawa framework. Results: Procurement-level quality assurance was strong: all products underwent quality testing, and 94.6% met pharmacopoeial standards. Internal warehouse handling accuracy and electronic order processing through the logistics management information system also met benchmark targets. In contrast, major downstream gaps were identified. Forecasting discrepancies reached 49.5%; supplier on-time delivery was low; warehouse storage utilization exceeded recommended capacity; inventory accuracy remained below target; and order-filling performance was poor at 38%. These gaps were associated with high stockout rates of 49.7% and inconsistent medicine availability across service delivery points, indicating misalignment between governance functions and downstream operational performance. Conclusions: Centralized procurement strengthened upstream quality assurance but did not ensure reliable availability of medicines when downstream supply chain functions were weak. Persistent gaps in forecasting, supplier performance, warehousing, inventory management, and distribution were associated with reduced service readiness and greater reliance on emergency or decentralized procurement pathways, which may increase risks to medicine quality. Strengthening pharmaceutical supply chains requires integrated end-to-end performance management, supported by routine system-level audits, to align governance and operational functions and sustain access to quality-assured medicines.

Published in European Journal of Clinical and Biomedical Sciences (Volume 12, Issue 3)
DOI 10.11648/j.ejcbs.20261203.11
Page(s) 39-53
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2026. Published by Science Publishing Group

Keywords

Pharmaceutical Supply Chain, Faith-based Organization, Health System Performance, Medicine Availability, Supply Chain Audit, Inventory Management, Substandard and Falsified Medicines, Cameroon

References
[1] Yadav P. Health product supply chains in developing countries: diagnosis of the root causes of underperformance and an agenda for reform. Health Syst Reform. 2015; 1(2): 142-154.
[2] Lugada E, Ochola I, Kirunda A, Sembatya M, Mwebaze S, Olowo M, et al. Health supply chain system in Uganda: assessment of status and performance of health facilities. J Pharm Policy Pract. 2022; 15(1): 52.
[3] Leung NHZ, Chen A, Yadav P, Gallien J. The impact of inventory management on stock-outs of essential drugs in sub?Saharan Africa: secondary analysis of a field experiment in Zambia. PLoS One. 2016; 11(5): e0156026.
[4] World Health Organization. Substandard and falsified medical products. Geneva: WHO; 2024. Available from:
[5] Access to Medicine Foundation. Access to Medicine Index 2024: evaluating pharmaceutical companies in expanding access to healthcare products in low- and middle-income countries. Amsterdam: Access to Medicine Foundation; 2024. Available from:
[6] World Health Organization. Substandard and falsified medical products: report by the Director-General. Executive Board 156th session, EB156/11. Geneva: WHO; 2025. Available from:
[7] United Nations Office on Drugs and Crime; World Health Organization. Contaminated medicines and integrity of the pharmaceutical excipients supply chain. Vienna and Geneva: UNODC and WHO; 2025. Available from:
[8] Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, et al. Prevalence and estimated economic burden of substandard and falsified medicines in low? and middle?income countries: a systematic review and meta?analysis. JAMA Netw Open. 2018; 1(4): e181662.
[9] Mugisha F, Arinaitwe A, Ekirapa?Kiracho E. Pharmaceutical supply chain performance in Uganda: evidence from public health facilities. BMC Health Serv Res. 2021; 21: 1156.
[10] Chopra S, Meindl P. Supply chain management: strategy, planning, and operation. 7th ed. Boston: Pearson; 2019.
[11] Kim DY. Relationship between supply chain integration and performance. Oper Manag Res. 2013; 6(1-2): 74-90.
[12] Pharmaceutical Supply Chain Initiative. PSCI audit program: preparation, on-site audit, and reporting. Washington (DC): PSCI; 2024. Available from:
[13] USAID Global Health Supply Chain Program-Procurement and Supply Management. GHSC-PSM FY 2024 Q4 quarterly report. Washington (DC): USAID GHSC-PSM; 2025. Available from:
[14] Ministry of Health Ghana. Ghana Health Supply Chain Master Plan 2025-2029. Accra: Ministry of Health; 2025. Available from:
[15] Mekonnen BA, Worku MC, Tefera BB. Evaluation of logistics management information system and availability of non-program tracer drugs in public health facilities in Bahir Dar City, Northwest Ethiopia. PLoS One. 2024; 19(4): e0302319.
[16] Milulu A, Mwita S, Basinda N. Electronic logistic management information system in public health facilities and its implications for the medicine supply chain in Singida District Council, Tanzania. Pharmacy. 2024; 12(4): 112.
[17] Mekonen ZT, Cho DJ, Fenta TG. Health commodities logistics management information system performance at public health facilities of Amhara region, Ethiopia. Front Public Health. 2025; 13: 1545429.
[18] Ishikawa K. Guide to quality control. Tokyo: Asian Productivity Organization; 1986.
[19] Fryze I, Naughton BD. Substandard and falsified medicine recalls in the legitimate supply chain: a systematic review of evidence. BMJ Open. 2025; 15(10): e103672.
[20] Herold DM, Marzantowicz Ł. Supply chain responses to global disruptions and ripple effects: an institutional complexity perspective. Oper Manag Res. 2023; 16: 2213-2224.
[21] Katsaliaki K, Galetsi P, Kumar S. Supply chain disruptions and resilience: a major review and future research agenda. Ann Oper Res. 2021; 319(1): 965-1007.
[22] World Health Organization. Health systems governance. Geneva: WHO; 2025. Available from:
[23] Matinheikki J, Kauppi K, Brandon-Jones A, van Raaij EM. Making agency theory work for supply chain relationships: a systematic review across four disciplines. Int J Oper Prod Manag. 2022; 42(13): 299-334.
[24] Nepomnyashchiy L, Baker P, Chovitz B. USAID’s role in global health supply chain programs and implications of aid cuts: a rapid review. Washington (DC): Center for Global Development; 2025. Available from:
[25] Bilal AI, Bititci US, Fenta TG. Effective supply chain strategies in addressing demand and supply uncertainty: a case study of Ethiopian Pharmaceutical Supply Services. Pharmacy. 2024; 12(5): 132.
[26] Duwiejua M, Steele P, Lalvani P, Leab D, Matowe L, Moody J. Promising practices in capacity development for health supply chains in resource-constrained countries. Glob Health Sci Pract. 2025; 13(Suppl 1): e2300208.
[27] Oldfield L, Penm J, Mirzaei A, Moles R. Prices, availability, and affordability of adult medicines in 54 low-income and middle-income countries: evidence based on a secondary analysis. Lancet Glob Health. 2025; 13(1): e50-e58.
[28] George S, Elrashid S. Inventory management and pharmaceutical supply chain performance of hospital pharmacies in Bahrain: a structural equation modeling approach. SAGE Open. 2023; 13(1): 21582440221149717.
Cite This Article
  • APA Style

    Ngum, S., Teke, G. N., Ndonku, S. A., Mobit, M. O., Afungchwi, G. M., et al. (2026). Centralized Faith-based Pharmaceutical Supply Chain Performance in Cameroon: A System-level Audit. European Journal of Clinical and Biomedical Sciences, 12(3), 39-53. https://doi.org/10.11648/j.ejcbs.20261203.11

    Copy | Download

    ACS Style

    Ngum, S.; Teke, G. N.; Ndonku, S. A.; Mobit, M. O.; Afungchwi, G. M., et al. Centralized Faith-based Pharmaceutical Supply Chain Performance in Cameroon: A System-level Audit. Eur. J. Clin. Biomed. Sci. 2026, 12(3), 39-53. doi: 10.11648/j.ejcbs.20261203.11

    Copy | Download

    AMA Style

    Ngum S, Teke GN, Ndonku SA, Mobit MO, Afungchwi GM, et al. Centralized Faith-based Pharmaceutical Supply Chain Performance in Cameroon: A System-level Audit. Eur J Clin Biomed Sci. 2026;12(3):39-53. doi: 10.11648/j.ejcbs.20261203.11

    Copy | Download

  • @article{10.11648/j.ejcbs.20261203.11,
      author = {Samuel Ngum and Gerald Ngo Teke and Signang Alberic Ndonku and Mbohjim Othniel Mobit and Glenn Mbah Afungchwi and Abenwie Suh Nchang and Munfi Francis Nyincho and Ngah Edward Ndze and Charles Ntungwen Fokunang},
      title = {Centralized Faith-based Pharmaceutical Supply Chain Performance in Cameroon: A System-level Audit},
      journal = {European Journal of Clinical and Biomedical Sciences},
      volume = {12},
      number = {3},
      pages = {39-53},
      doi = {10.11648/j.ejcbs.20261203.11},
      url = {https://doi.org/10.11648/j.ejcbs.20261203.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ejcbs.20261203.11},
      abstract = {Background: Centralized pharmaceutical procurement can strengthen medicine quality assurance and reduce exposure to substandard and falsified medicines in low- and middle-income countries. However, medicine availability depends on how well procurement, forecasting, warehousing, inventory management, information systems, and distribution function as an integrated system. This study assessed the system-level performance of a centralized, faith-based pharmaceutical supply chain in Cameroon to identify operational strengths, performance gaps, and governance-related risks that affect sustained access to quality-assured medicines. Methods: A cross-sectional pharmaceutical supply chain audit was conducted over a 1-year period using the Pharmaceutical Supply Chain Initiative tripartite audit framework. Performance was assessed across forecasting, procurement, supplier sourcing, warehousing, inventory management, use of logistics management information systems, and distribution, using adapted USAID-recommended indicators. Quantitative benchmarking was complemented by participatory root-cause analysis using the Ishikawa framework. Results: Procurement-level quality assurance was strong: all products underwent quality testing, and 94.6% met pharmacopoeial standards. Internal warehouse handling accuracy and electronic order processing through the logistics management information system also met benchmark targets. In contrast, major downstream gaps were identified. Forecasting discrepancies reached 49.5%; supplier on-time delivery was low; warehouse storage utilization exceeded recommended capacity; inventory accuracy remained below target; and order-filling performance was poor at 38%. These gaps were associated with high stockout rates of 49.7% and inconsistent medicine availability across service delivery points, indicating misalignment between governance functions and downstream operational performance. Conclusions: Centralized procurement strengthened upstream quality assurance but did not ensure reliable availability of medicines when downstream supply chain functions were weak. Persistent gaps in forecasting, supplier performance, warehousing, inventory management, and distribution were associated with reduced service readiness and greater reliance on emergency or decentralized procurement pathways, which may increase risks to medicine quality. Strengthening pharmaceutical supply chains requires integrated end-to-end performance management, supported by routine system-level audits, to align governance and operational functions and sustain access to quality-assured medicines.},
     year = {2026}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Centralized Faith-based Pharmaceutical Supply Chain Performance in Cameroon: A System-level Audit
    AU  - Samuel Ngum
    AU  - Gerald Ngo Teke
    AU  - Signang Alberic Ndonku
    AU  - Mbohjim Othniel Mobit
    AU  - Glenn Mbah Afungchwi
    AU  - Abenwie Suh Nchang
    AU  - Munfi Francis Nyincho
    AU  - Ngah Edward Ndze
    AU  - Charles Ntungwen Fokunang
    Y1  - 2026/07/22
    PY  - 2026
    N1  - https://doi.org/10.11648/j.ejcbs.20261203.11
    DO  - 10.11648/j.ejcbs.20261203.11
    T2  - European Journal of Clinical and Biomedical Sciences
    JF  - European Journal of Clinical and Biomedical Sciences
    JO  - European Journal of Clinical and Biomedical Sciences
    SP  - 39
    EP  - 53
    PB  - Science Publishing Group
    SN  - 2575-5005
    UR  - https://doi.org/10.11648/j.ejcbs.20261203.11
    AB  - Background: Centralized pharmaceutical procurement can strengthen medicine quality assurance and reduce exposure to substandard and falsified medicines in low- and middle-income countries. However, medicine availability depends on how well procurement, forecasting, warehousing, inventory management, information systems, and distribution function as an integrated system. This study assessed the system-level performance of a centralized, faith-based pharmaceutical supply chain in Cameroon to identify operational strengths, performance gaps, and governance-related risks that affect sustained access to quality-assured medicines. Methods: A cross-sectional pharmaceutical supply chain audit was conducted over a 1-year period using the Pharmaceutical Supply Chain Initiative tripartite audit framework. Performance was assessed across forecasting, procurement, supplier sourcing, warehousing, inventory management, use of logistics management information systems, and distribution, using adapted USAID-recommended indicators. Quantitative benchmarking was complemented by participatory root-cause analysis using the Ishikawa framework. Results: Procurement-level quality assurance was strong: all products underwent quality testing, and 94.6% met pharmacopoeial standards. Internal warehouse handling accuracy and electronic order processing through the logistics management information system also met benchmark targets. In contrast, major downstream gaps were identified. Forecasting discrepancies reached 49.5%; supplier on-time delivery was low; warehouse storage utilization exceeded recommended capacity; inventory accuracy remained below target; and order-filling performance was poor at 38%. These gaps were associated with high stockout rates of 49.7% and inconsistent medicine availability across service delivery points, indicating misalignment between governance functions and downstream operational performance. Conclusions: Centralized procurement strengthened upstream quality assurance but did not ensure reliable availability of medicines when downstream supply chain functions were weak. Persistent gaps in forecasting, supplier performance, warehousing, inventory management, and distribution were associated with reduced service readiness and greater reliance on emergency or decentralized procurement pathways, which may increase risks to medicine quality. Strengthening pharmaceutical supply chains requires integrated end-to-end performance management, supported by routine system-level audits, to align governance and operational functions and sustain access to quality-assured medicines.
    VL  - 12
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Sections